Immunological evaluation of personalized peptide vaccination in combination with UFT and UZEL for metastatic colorectal carcinoma patients

Cancer Immunology, Immunotherapy

Volumn 58, Issue 11, 2009, Pages 1845-1854

  Hattori, Takashi ^a   Mine, Takashi ^b   Komatsu, Nobukazu ^b   Yamada, Akira ^b   Itoh, Kyogo ^b   Shiozaki, Hitoshi ^a   Okuno, Kiyotaka ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cytotoxic T lymphocyte; Metastatic colorectal cancer; Peptide specific IgG response; Peptide vaccine; Personalized treatment

Indexed keywords

FOLINATE CALCIUM; GAMMA INTERFERON; IMMUNOGLOBULIN G; PEPTIDE VACCINE; UFT; 1 UFT PROTOCOL; 1-UFT PROTOCOL; ANTINEOPLASTIC AGENT; CANCER VACCINE; FOLINIC ACID; HLA A ANTIGEN; HLA A2 ANTIGEN; HLA A24 ANTIGEN; TEGAFUR; URACIL;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLITIS; COLORECTAL CARCINOMA; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; HYPERBILIRUBINEMIA; IMMUNE RESPONSE; INJECTION SITE REACTION; LYMPHOCYTOPENIA; MALE; METASTASIS; NEUTROPENIA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SKIN ULCER; TREATMENT RESPONSE; VACCINATION; BIOSYNTHESIS; COLORECTAL TUMOR; IMMUNOLOGY; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HLA-A ANTIGENS; HLA-A2 ANTIGEN; HUMANS; INTERFERON-GAMMA; LEUCOVORIN; MALE; MIDDLE AGED; T-LYMPHOCYTES, CYTOTOXIC; TEGAFUR; URACIL; VACCINATION;

EID: 70349766001     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-009-0695-6     Document Type: Article

References (24)

1. PA Antony CA Piccirillo A Akpinarli et al. 2005 CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4 + T helper cells and hindered by naturally occurring T regulatory cells J Immunol 174 2591 2601
2. M Barve J Bender N Senzer et al. 2008 Induction of immune response and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer J Clin Oncol 27 4418 4425
3. Becker JC, Wobser M, Hofmeister V et al (2008) Safety, immunologenicity and clinical response of a survivin-based peptide vaccine in therapy-resistant advanced cancer: Results from phase I/II trial. Abstract of Annual Meeting of American Society of Clinical Oncology J Clin Oncol 26:3046, 143pp
4. I Bolonaki A Kotsakis E Papadimitraki et al. 2007 Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide J Clin Oncol 25 2727 2734
5. JY Douillard PM Hoff JR Skillings et al. 2002 Multicenter phase study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer J Clin Oncol 20 3605 3616
6. N Harashima K Tanaka T Sasatomi et al. 2001 Recognition of the Lck tyrosine kinase as a tumor antigen by cytotoxic T lymphocytes of cancer patients with distant metastases Eur J Immunol 31 323 332
7. N Hida Y Maeda K Katagiri et al. 2002 A simple culture protocol to detect peptide-specific cytotoxic T lymphocyte precursors in the circulation Cancer Immunol Immunother 51 219 228
8. M Ito S Shichijo Y Miyagi et al. 2000 Identification of SART3-derived peptides capable of inducing HLA-A2-restricted and tumor specific CTLs in cancer patients with different HLA-A2 subtypes Int J Cancer 88 633 639
9. EA Joura S Leodolter M Hernandez-Avila et al. 2007 Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials Lancet 369 1693 1702
10. M Kikuchi M Nakao Y Inoue et al. 1999 Identification of a SART-1-derived peptide capable of inducing HLA-A24-restricted and tumor-specific cytotoxic T lymphocytes Int J Cancer 81 459 466
11. N Komatsu S Shichijo M Nakagawa et al. 2004 New multiplexed flow cytometric assay to measure anti-peptide antibody: a novel tool for monitoring immune responses to peptides used for immunization Scand J Clin Lab Inest 64 535 545
12. T Mine Y Sato M Noguchi et al. 2004 Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific cellular responses Clin Cancer Res 10 929 937
13. Y Miyagi N Imai T Sasatomi et al. 2001 Induction of cellular immune responses to tumor cells and peptides in colorectal cancer patients by vaccination with SART3 peptide Clin Cancer Res 12 3950 3962
14. M Nakao S Shichijo T Imaizumi et al. 2000 Identification of a gene coding for a new squamous cell carcinoma antigen recognized by the CTL J Immunol 164 2565 2574
15. M Noguchi T Mine A Yamada et al. 2007 Combination therapy of personalized peptide vaccination and low-dose estramustine phosphate for metastatic hormone refractory prostate cancer patients: an analysis of prognostic factors in the treatment Oncol Res 16 341 349
16. J Paavonen D Jenkins FX Bosch et al. 2007 Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial Lancet 369 2161 2170
17. T Sasatomi Y Suefuji K Matsunaga et al. 2002 Expression of tumor rejection antigens in colorectal carcinomas Cancer 94 1636 1641
18. Y Sato T Fujiwara T Mine et al. 2007 Immunological evaluation of personalized peptide vaccination in combination with a 5-fluorouracil derivative (TS-1) for advanced gastric or colorectal carcinoma patients Cancer Sci 7 1113 1119
19. K Shirao PM Hoff A Ohtsu et al. 2004 Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV J Clin Oncol 22 3466 3474
20. GJ Ullenhag JE Frödin M Jeddi-Tehrani et al. 2004 Durable carcinoembryonic antigen (CEA)-specific humoral and cellular immune responses in colorectal carcinoma patients vaccinated with recombinant CEA and granulocyte/macrophage colony-stimulating factor Clin Cancer Res 15 3273 3328
21. C Wood P Srivastava R Bukowski et al. 2008 An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial Lancet 372 145 154
22. N Yajima R Yamanaka T Mine et al. 2005 Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma Clin Cancer Res 11 5900 5911
23. H Yanagimoto T Mine K Yamamoto et al. 2007 Immunological evaluation of personalized peptide vaccination with gemcitabine for pancreatic cancer Cancer Sci 12 605 611
24. D Yang M Nakao S Shichijo et al. 1999 Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients Cancer Res 59 4056 4063